Vagus Nerve Stimulation for Gastroparesis: What Research Shows and What Remains Unproven

Vagus nerve stimulation is being studied for gastroparesis, but it has not been established as a standard treatment. Small studies have reported symptom improvement in some patients, yet the evidence remains limited and does not show that all forms of VNS improve gastric emptying or produce the same results.

This distinction matters because “vagus nerve stimulation” can describe very different technologies. A handheld device used on the neck, an ear-based taVNS device and an implanted gastric electrical stimulator do not stimulate the same target in the same way. Their evidence should therefore be evaluated separately rather than grouped together as one treatment.

Can Vagus Nerve Stimulation Help Gastroparesis?

Early research suggests that vagus nerve stimulation may help symptoms in some people with gastroparesis, but the evidence is not strong enough to establish it as a routine gastroparesis treatment.

One of the most relevant studies was a small Stanford pilot involving 15 people with mild-to-moderate idiopathic gastroparesis. Researchers used non-invasive cervical vagus nerve stimulation and reported that 6 participants reached the study's predefined symptom-response threshold. Overall symptom scores also improved during treatment.

That result is encouraging, but the study had no sham-stimulation group and included only a small number of participants. Without a control group, it is difficult to separate the effect of stimulation from symptom fluctuation, expectation effects or other changes occurring during the study.

The gap becomes more obvious when stricter evidence standards are applied. A 2025 systematic review of sham-controlled VNS trials in gastrointestinal disorders included seven trials and 644 participants, but none of the eligible trials specifically studied gastroparesis.

That does not mean gastroparesis research does not exist. It means the direct evidence has not yet reached the same level of controlled clinical testing available for some other gastrointestinal conditions.

Why Is the Vagus Nerve Involved in Gastroparesis?

The vagus nerve is relevant because it participates in the communication between the brain and stomach that helps coordinate sensation, movement and digestive function. That makes it a reasonable target for neuromodulation research, but it does not mean gastroparesis can be reduced to a single vagus nerve problem.

How the Vagus Nerve Helps Regulate Gastric Motility

Signals traveling from the stomach toward the brain help communicate stretch, fullness and other visceral sensations. Signals traveling in the opposite direction contribute to the coordination of gastric movement and other autonomic functions involved in digestion.

However, gastric emptying also depends on the enteric nervous system, stomach smooth muscle, interstitial cells of Cajal, pyloric function and other local mechanisms. A problem anywhere in this system can alter gastric motility.

This is why stimulating the vagus nerve is biologically plausible without implying that the vagus nerve controls gastric emptying by itself.

Does Gastroparesis Always Mean Vagus Nerve Damage?

No. Gastroparesis does not automatically mean that the vagus nerve is damaged.

Vagal dysfunction can contribute to some cases. Diabetes-related autonomic neuropathy may affect vagal function, and certain operations involving the stomach or upper gastrointestinal tract can injure vagal pathways. But many people have idiopathic gastroparesis, where no single structural nerve injury can be identified.

Even when vagal dysfunction is involved, another assumption should be avoided: stimulating the vagus nerve does not necessarily “repair” a damaged nerve. VNS changes neural signaling; it should not be described as restoring a physically injured vagus nerve unless a specific study demonstrates that effect.

Gastroparesis is therefore better understood as a disorder of gastric function that can arise through several mechanisms, with vagal dysfunction representing one possible contributor rather than a universal cause.

What Do Clinical Studies Show About Vagus Nerve Stimulation for Gastroparesis?

What Did the Stanford VNS Study Find?

The Stanford pilot study used a handheld non-invasive cervical VNS device in 15 people with idiopathic gastroparesis. Six participants met the predefined primary symptom-response endpoint, and average gastroparesis symptom scores improved during the treatment period.

Researchers also measured gastric emptying. Gastric emptying half-time decreased from approximately 155 minutes to 129 minutes. However, the reported statistical result was p=0.053, slightly above the conventional 0.05 threshold normally used to define statistical significance.

That difference is important. It would be inaccurate to say the trial proved that VNS accelerated gastric emptying.

The researchers also found that symptom improvement did not closely track changes in gastric emptying. Someone could feel better without showing a comparable change in the emptying test, while a change in gastric emptying would not necessarily predict how much symptom relief that person experienced.

The study therefore supports an early clinical signal, not confirmed efficacy. Its small size and lack of a sham group remain major limitations. The original study can be reviewed in the published pilot research on non-invasive VNS for idiopathic gastroparesis.

Why Have Other VNS Studies Reported Different Results?

Later studies show why one positive pilot should not be treated as a final answer.

A 2024 double-blind, sham-controlled trial studied 145 people with diabetes, autonomic neuropathy and gastrointestinal symptoms. Active cervical transcutaneous VNS did not produce a significant advantage over sham stimulation for the primary gastrointestinal symptom outcome.

This trial was not restricted to people with confirmed gastroparesis, so it cannot be used to conclude that VNS does not work for gastroparesis. It does, however, provide an important counterweight to smaller uncontrolled studies: a positive signal may weaken or disappear when treatment is compared with sham stimulation.

Differences in patient population, disease mechanism, treatment duration, stimulation protocol and outcome measurement can all change the result. The 2024 randomized cervical tVNS trial therefore lowers confidence in broad claims that vagus nerve stimulation reliably improves gastrointestinal symptoms.

Why Results From Other Digestive Disorders Cannot Prove Gastroparesis Benefits

Positive findings in functional dyspepsia, IBS, constipation or other gastrointestinal disorders should not be used as substitutes for gastroparesis evidence.

The disorders may share symptoms such as fullness, abdominal discomfort or altered bowel function, but they do not have the same diagnostic criteria or underlying physiology. Gastroparesis specifically involves objectively delayed gastric emptying in the absence of mechanical obstruction.

A study showing less abdominal pain in IBS or improved bowel movements in constipation therefore does not demonstrate that VNS improves delayed gastric emptying in gastroparesis.

The same boundary applies to stimulation parameters. Even if two devices use similar frequencies or both target vagal pathways, that does not make their clinical effects interchangeable. Evidence should follow the disease, device, protocol and outcome actually studied.

Does Vagus Nerve Stimulation Improve Gastric Emptying or Mainly Relieve Symptoms?

Current research does not show that symptom improvement and faster gastric emptying consistently occur together.

These outcomes answer different questions:

Gastroparesis symptoms do not always correlate closely with the degree of delayed gastric emptying. That is why a therapy can potentially reduce nausea or discomfort without normalizing gastric motility.

The Stanford pilot illustrated this problem directly: clinical response and changes in gastric emptying were not closely aligned. Similar observations have also been made with gastric electrical stimulation, where some patients may experience improvement in nausea or vomiting without a parallel acceleration in gastric emptying.

For anyone evaluating VNS research, “patients felt better” and “their stomach emptied faster” should therefore be treated as separate findings.

Are Handheld Vagus Nerve Stimulators and Gastric Pacemakers the Same?

No. They are different technologies with different stimulation targets and different evidence.

A gastric electrical stimulator is sometimes called a “gastric pacemaker,” but it is not a vagus nerve stimulator. The electrodes act on the stomach rather than delivering cervical or auricular vagus nerve stimulation.

Clinical guidelines have allowed gastric electrical stimulation to be considered in selected medically refractory cases, although evidence remains limited and recommendations are cautious. That evidence cannot be transferred to a handheld or ear-based VNS device.

The same rule applies in the opposite direction. A study of cervical nVNS does not establish that every ear-based vagus nerve stimulation device produces the same effect.

ZenoWell Luna Plus, for example, is an ear-based taVNS wellness device. Its Digestion mode is designed for a relaxation-oriented routine around mild post-meal discomfort, consistent with ZenoWell's intended wellness use. It has not been established as a treatment for gastroparesis, and its settings should not be interpreted as a clinically validated gastroparesis protocol.

What Should You Know Before Trying Vagus Nerve Stimulation for Gastroparesis?

Before considering a vagus nerve stimulation device, first check whether the evidence actually matches the condition and technology you are considering.

A study involving functional dyspepsia is not automatically gastroparesis evidence. A study using cervical nVNS is not automatically evidence for an ear-worn taVNS device. A study reporting symptom improvement is also different from one showing objectively faster gastric emptying.

People with gastroparesis may have additional concerns such as diabetes-related autonomic dysfunction, dehydration, nutritional deficiencies or other medical conditions. These can affect whether electrical stimulation is appropriate and should be considered individually rather than assumed from general wellness information.

Extra caution is warranted for people with relevant cardiac rhythm problems, recurrent fainting, implanted electronic devices or other conditions listed in a device's contraindications.

Do not attempt to reproduce research protocols by modifying TENS units, changing electrode positions or copying stimulation settings from online discussions. The device, stimulation site and protocol used in a clinical study are part of the intervention being tested.

Persistent vomiting, inability to keep fluids down, worsening dehydration or significant nutritional problems require medical assessment rather than experimentation with a stimulation device.

Vagus Nerve Stimulation for Gastroparesis FAQs

Does Gastroparesis Mean Your Vagus Nerve Is Damaged?

No. Vagal dysfunction or injury may contribute to some cases, particularly in diabetes or after certain surgeries, but gastroparesis has multiple possible mechanisms and does not prove that the vagus nerve is damaged.

Can Non-Invasive Vagus Nerve Stimulation Treat Gastroparesis?

Current evidence is insufficient to establish non-invasive VNS as a standard effective treatment for gastroparesis. Small early studies have reported promising symptom changes, but stronger sham-controlled trials are still needed.

Is a Gastric Pacemaker a Vagus Nerve Stimulator?

No. Gastric electrical stimulation uses implanted electrodes acting on the stomach, while vagus nerve stimulation targets neural pathways at the neck or ear. Their evidence and mechanisms should be evaluated separately.

Are Ear-Based Vagus Nerve Stimulators Proven to Improve Gastric Emptying?

No convincing direct clinical evidence currently shows that consumer ear-based taVNS devices reliably improve gastric emptying in people with gastroparesis. Evidence from other gastrointestinal disorders or other VNS technologies cannot establish that effect.